AC
TBIO

Athanor Capital’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Athanor Capital’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,485
Closed -$272K – 997
2021
Q1 		$272K Buy
16,485
+5,200
+46% +$118K 0.01% 614
2020
Q4 		$208K Buy
+11,285
New +$202K ﹤0.01% 651

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Athanor Capital's TBIO Position: Q2 2021 in Review

Athanor Capital sold out of Translate Bio, Inc. Common Stock (TBIO) in Q2 2021, closing a stake of 16,485 shares — an estimated $272K sold.

Athanor Capital first reported a position in TBIO in Q4 2020 and held it in 2 quarters. The position peaked at $272K in Q1 2021. 145 funds tracked by Wall St. Rank hold TBIO as of Q2 2021.

  • Athanor Capital reported no remaining Translate Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 16,485 Translate Bio, Inc. Common Stock shares in Q2 2021, an estimated $272K.
  • Athanor Capital first reported a position in Translate Bio, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Athanor Capital's Translate Bio, Inc. Common Stock position peaked at $272K in Q1 2021.
  • 145 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.